Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.57 |
| ▸ | CTSB | P07858 | 5/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187252 | 1.00 | CTSL (0.57) | CTSLCTSBMMEACECPA1 | |
| SCHEMBL18228994 | 0.91 | CTSL (0.64) | CTSLCTSBCTSSCTSK | |
| SCHEMBL20187261 | 0.89 | CTSL (0.55) | CTSLCTSBTGM2ALDH1A1 | |
| SCHEMBL20187260 | 0.89 | CTSL (0.55) | CTSLCTSBTGM2ALDH1A1 | |
| SCHEMBL18229063 | 0.87 | CTSL (0.51) | CTSLCTSBMMEACECPA1 | |
| SCHEMBL20187271 | 0.87 | MME (0.52) | CTSLCTSBMMEACECPA1 | |
| SCHEMBL20187268 | 0.87 | MME (0.52) | CTSLCTSBMMEACECPA1 | |
| SCHEMBL18229001 | 0.86 | CTSL (0.51) | CTSLCTSBMMEACECPA1 | |
| SCHEMBL20187248 | 0.86 | CTSL (0.51) | CTSLCTSBMMEACECPA1 | |
| SCHEMBL7317573 | 0.83 | HDAC8 (0.64) | CTSLCTSBF2HDAC8CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280721-B1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | ONCOPEPTIDES AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | CBR3, GRHPR, CTH | CTSL 1776/4885CTSB 1017/4885MME 270/4885 |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | CBR3, GRHPR, CTH | CTSL 1776/4885CTSB 1017/4885MME 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.